Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-02-26

FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

FDA approves a supplemental application for Taclonex (calcipotriol and betamethone dipropionate) from LEO Pharma Inc., updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TACLONEX (calcipotriol and betamethone dipropionate)

Snippet

SUPPL AP for TACLONEX (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)